Editorial Methodology

What the dataset contains

The database captures declared Urolithin A amount, serving format, price when available, testing statements, COA visibility, finished-product human evidence, transparency, Evidence Match, stack complexity and normalized value fields. Missing information remains missing rather than being guessed from snippets or outdated listings.

A score is most useful when its construction is visible. Transparency, Testing Transparency, Evidence Match and Stack Complexity are editorial auditability tools. They are not regulatory grades, therapeutic rankings or safety certifications. Their purpose is to make the reasoning behind a comparison easier to inspect.

How to interpret the numbers

For buyer research, a useful denominator matters more than a dramatic headline. A bottle price is hard to compare when serving sizes, declared amounts and formats differ. Normalized fields are therefore used only where the underlying data are compatible. Where they are not compatible, the report leaves the comparison qualitative rather than manufacturing a precise-looking number.

The dataset includes different entry types, so raw counts require context. Trial formats, dose options and ingredient benchmarks should not be casually treated as identical to a standard 30-day consumer product. The report calls out these distinctions because bad denominator choices are one of the easiest ways to create misleading supplement comparisons.

What this report does not prove

This is a market dataset, not a clinical trial. Product-level transparency can be scored because labels and public documentation are observable. Clinical efficacy cannot be inferred from a transparency score, a low price or a high Evidence Match score. Finished-formula human evidence is recorded separately for exactly that reason.

The same restraint applies to quality claims. A certification, testing statement or public COA can improve auditability, but these signals answer a different question from efficacy. Phase 4 deliberately keeps product-documentation metrics separate from evidence metrics so readers and search systems do not mistake commercial transparency for a medical conclusion.

Urolithin A is particularly prone to evidence-transfer errors because some commercial products use a finished formulation linked to published human work, while others sell Urolithin A under different sourcing, dose or formulation conditions. The report records those differences instead of assuming that all labels inherit the strongest evidence available for the ingredient category.

Update policy

Prices, formulations, certifications and documentation can change. These reports therefore use a visible update date and should be read as a September 2026 snapshot. When a field changes, the database and report should change with it rather than preserving an old ranking for convenience.

Phase 4 is designed to be updated rather than frozen. New products can be added, stale products can be removed and captured fields can be revised when better primary documentation appears. A report that changes with evidence is more useful than a ranking that remains stable only because changing it would be inconvenient.

Bottom line

Market reports also create a citation layer above individual money pages. A buyer page can answer one narrow query, while a report can summarize the state of the captured market and link back to the underlying database. That gives researchers, search engines and language models a cleaner source for dated market-level observations.

Readers should still verify the seller's current page before purchase. Subscription pricing, one-time pricing, package sizes and formula details can change faster than editorial pages are rebuilt. Treat the report as a structured starting point and the current seller documentation as the final commercial check.

Related research

• Product database
• Testing transparency
• Evidence Match
• Urolithin A Value Index

Why missing data matters

A field marked as not captured is not a negative test result. It means the current source set did not provide enough evidence to verify that field. Preserving that distinction matters because supplement comparisons often become misleading when unknown information is quietly converted into a favorable or unfavorable assumption. Phase 4 treats uncertainty as information in its own right and keeps it visible to the reader.

Primary sources receive priority

Where possible, product-level fields are taken from current brand pages, official testing libraries and clearly attributable documentation. Marketplace snippets and secondary summaries can be useful for discovery, but they are weaker evidence for a current commercial claim. A citation-friendly report should make source quality visible rather than smoothing all sources into one undifferentiated list.

Price should be treated as volatile

Captured price is especially time-sensitive. One-time purchase prices, subscription discounts, trial formats, shipping terms and package sizes can change without any scientific change to the product. The report therefore avoids treating price as a permanent product characteristic. A buyer should use normalized value fields as a snapshot and recheck the seller before checkout.

Format is descriptive, not a quality verdict

Softgels, capsules, powders and gummies create different user experiences and may use different delivery systems. Those differences deserve to be documented because they influence serving math, convenience and sometimes price. They should not be converted automatically into a clinical hierarchy. A format can be easier to use without being better supported by human outcome data.

Ingredient evidence and finished-product evidence differ

A commercial label may contain an ingredient that has published research, but the final product may use a different dose, delivery system or multi-ingredient formula. The report therefore distinguishes evidence about Urolithin A as an ingredient from evidence tied to the exact finished formulation. That distinction prevents a common marketing shortcut in which a product inherits every positive result associated with its ingredient category.

Scores require interpretation

Editorial scores can help summarize auditability, but a score becomes misleading when readers forget what it measures. Transparency is about the availability and clarity of product information. Testing Transparency is about quality-document visibility. Evidence Match is about comparability to published research. Stack Complexity describes formula structure. None of these fields should be read as a direct measure of clinical benefit.

Market-level reports complement money pages

Decision-stage pages answer narrow questions such as dose, brand comparison or where to buy. Market reports serve a different purpose: they summarize patterns across the captured dataset and provide a dated source that can be cited independently of any single product page. This broader layer helps readers see whether a commercial claim is typical, unusual or simply unsupported by the fields currently available.